PMID- 33569208
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 13
IP  - 1
DP  - 2021 Jan
TI  - Evaluation of pembrolizumab for the treatment of advanced non-small cell lung 
      cancer: a retrospective, single-centre, single-arm study.
PG  - 282-290
LID - 10.21037/jtd-20-3413 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) provided a paradigm shift for 
      advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical 
      prognosis of such patients. Pembrolizumab is a humanized anti-programmed death 
      cell protein 1 (PD-1) monoclonal antibody, approved for the treatment of patients 
      with advanced or metastatic NSCLC. This article investigated and reported on the 
      efficacy and safety of pembrolizumab in the treatment of advanced NSCLC in our 
      center since 2019. METHODS: Patients with clinical stage III-IV NSCLC treated 
      with pembrolizumab for >/=4 cycles were enrolled as participants in this study. 
      Pembrolizumab was administered intravenously at a dose of 2 mg/kg every 3 weeks. 
      A cycle was defined as 3 weeks of treatment. We assessed the efficacy and safety 
      of pembrolizumab through the collection of researcher-assessed tumor response, 
      survival, and safety data. RESULTS: A total of 24 patients were included in this 
      study. The median follow-up time was 9 months (3-20 months) and the median period 
      of pembrolizumab therapy was 7 cycles (4-21 cycles). The objective response rate 
      (ORR) was 45.8% and disease control rate (DCR) was 70.8%. The median overall 
      survival (OS) and progression-free survival (PFS) times were not reached. A total 
      of 2 programmed death-ligand 1 (PD-L1)-negative participants were treated with 
      pembrolizumab combined with chemotherapy and there was no significant progression 
      during the follow-up period. During the follow-up period, 8 patients underwent 
      surgery. The major pathological response (MPR) was 75% and pathological complete 
      response (pCR) was 50%. A case that was preoperatively diagnosed with clinical 
      stage IV achieved pCR after 6 cycles of pembrolizumab combined with chemotherapy. 
      The incidence of adverse effects (AEs) was 83.3%, and 16.7% of these were serious 
      AEs (grade >/=3), which was similar to the incidence reported in previous studies. 
      CONCLUSIONS: This real-world data supports the use of pembrolizumab for advanced 
      NSCLC, including those cases that are PD-L1 negative. More importantly, 
      pembrolizumab immunotherapy can also provide the potential of local treatment for 
      patients with advanced NSCLC, which has wide application prospects in the field 
      of surgery.
CI  - 2021 Journal of Thoracic Disease. All rights reserved.
FAU - Guo, Tianxing
AU  - Guo T
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Ding, Yun
AU  - Ding Y
AD  - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
FAU - Chen, Long
AU  - Chen L
AD  - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
FAU - Zhu, Lihuan
AU  - Zhu L
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Lin, Jinlan
AU  - Lin J
AD  - Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical 
      University Cancer Hospital, Fuzhou, China.
FAU - Zhang, Jiguang
AU  - Zhang J
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Huang, Yangyun
AU  - Huang Y
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Li, Wujin
AU  - Li W
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Lin, Rongjia
AU  - Lin R
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
FAU - Pan, Xiaojie
AU  - Pan X
AD  - Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian 
      Medical University, Fujian Provincial Hospital, Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7867846
OTO - NOTNLM
OT  - Pembrolizumab
OT  - advanced non-small cell lung cancer (NSCLC)
OT  - efficacy
OT  - immunotherapy
OT  - safety
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/jtd-20-3413). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/02/12 06:00
MHDA- 2021/02/12 06:01
PMCR- 2021/01/01
CRDT- 2021/02/11 05:54
PHST- 2021/02/11 05:54 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/12 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - jtd-13-01-282 [pii]
AID - 10.21037/jtd-20-3413 [doi]
PST - ppublish
SO  - J Thorac Dis. 2021 Jan;13(1):282-290. doi: 10.21037/jtd-20-3413.